title: Combined inhibition of BRAF and MEK in melanoma patients.
authors.affiliation: Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA. Electronic address: jinfante@tnonc.com.
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Infante
authors.affiliation: Cancer Research UK London Research Institute, and University College London Hospitals and Cancer Institute, London, UK.
authors.forename: Charles
authors.initials: C
authors.lastname: Swanton
mesh_terms: D001384:Azetidines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage*; D048493:Proto-Oncogene Proteins B-raf / Q000187:drug effects*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077484:Vemurafenib
chemical_list: D001384:Azetidines; D007211:Indoles; D010880:Piperidines; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf; C574276:cobimetinib